These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 16951206

  • 1. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
    Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS.
    Cancer Res; 2006 Sep 01; 66(17):8887-96. PubMed ID: 16951206
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12.
    Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H.
    Cancer Res; 1999 Aug 15; 59(16):4035-41. PubMed ID: 10463604
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
    Tatsumi T, Takehara T, Kanto T, Miyagi T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N.
    Cancer Res; 2001 Oct 15; 61(20):7563-7. PubMed ID: 11606395
    [Abstract] [Full Text] [Related]

  • 6. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K, Papworth GD, Watkins SC, Gambotto A, Yoshida J, Pollack IF, Okada H.
    Gene Ther; 2004 Nov 15; 11(21):1551-8. PubMed ID: 15343358
    [Abstract] [Full Text] [Related]

  • 7. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W, He L, Cao X.
    Zhonghua Yi Xue Za Zhi; 1999 Mar 15; 79(3):170-3. PubMed ID: 11601032
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
    Yuan X, Hu J, Belladonna ML, Black KL, Yu JS.
    Cancer Res; 2006 Mar 01; 66(5):2630-8. PubMed ID: 16510582
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells.
    Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J.
    Cell Immunol; 1999 Dec 15; 198(2):131-8. PubMed ID: 10648127
    [Abstract] [Full Text] [Related]

  • 11. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H.
    Oncology; 2005 Dec 15; 68(2-3):163-70. PubMed ID: 16006753
    [Abstract] [Full Text] [Related]

  • 12. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells.
    Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H.
    Cancer Gene Ther; 2003 Jul 15; 10(7):549-58. PubMed ID: 12833135
    [Abstract] [Full Text] [Related]

  • 13. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
    Yang AS, Lattime EC.
    Cancer Res; 2003 May 01; 63(9):2150-7. PubMed ID: 12727833
    [Abstract] [Full Text] [Related]

  • 14. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J.
    J Immunol; 1998 Dec 01; 161(11):6238-44. PubMed ID: 9834111
    [Abstract] [Full Text] [Related]

  • 15. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
    Murakami T, Tokunaga N, Waku T, Gomi S, Kagawa S, Tanaka N, Fujiwara T.
    Clin Cancer Res; 2004 Jun 01; 10(11):3871-80. PubMed ID: 15173096
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
    Zhang X, Munegowda MA, Yuan J, Wei Y, Xiang J.
    J Leukoc Biol; 2010 Aug 01; 88(2):393-403. PubMed ID: 20466823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.